UK markets open in 1 hour 52 minutes
  • NIKKEI 225

    30,139.89
    +468.19 (+1.58%)
     
  • HANG SENG

    30,345.61
    +627.37 (+2.11%)
     
  • CRUDE OIL

    63.40
    +0.18 (+0.28%)
     
  • GOLD FUTURES

    1,799.30
    +1.40 (+0.08%)
     
  • DOW

    31,961.86
    +424.51 (+1.35%)
     
  • BTC-GBP

    35,604.18
    -502.62 (-1.39%)
     
  • CMC Crypto 200

    1,006.90
    +12.24 (+1.23%)
     
  • ^IXIC

    13,597.97
    0.00 (0.00%)
     
  • ^FTAS

    3,795.06
    +23.72 (+0.63%)
     

IBA – ACQUISITION OF OWN SHARES

IBA SA
·2-min read

Tab_en_22022021

Tab
Tab
Tab

Immediate Release – February 22nd, 2021

Louvain-la-Neuve, Belgium, February 22nd, 2021 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on January 12th, 2021.

Under this program, IBA has requested a financial intermediary to repurchase up to 357.000 IBA ordinary shares on its behalf under the terms of a discretionary mandate agreement with validity until May 31st, 2021, effective as from January 13th, 2021, to cover the company’s obligations under a long term incentive plan for certain members of its personnel.

In the framework of this share buyback program, IBA repurchased 42.538 IBA shares on Euronext Brussels in the period from February 12th, 2021 up to and including February 19th, 2021, as follows:

Tab_en_22022021

These transactions included the purchase of a block of 23.592 shares at a price of 14,32 EUR/share, which was executed on February 12th, 2021 at 10.21 AM on the central order book of Euronext Brussels (XBRU).

The total number of shares purchased under this program therefore amounts to 140.098.

About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at www.iba-worldwide.com

Contact person

IBA
Christian Matton,
Chief Legal Officer
shareholderrelations@iba-group.com

Attachments